Article

You have full text access to this OnlineOpen article

Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor

  1. George T. Lountos1,
  2. Joseph E. Tropea1,
  3. Di Zhang1,
  4. Andrew G. Jobson2,
  5. Yves Pommier2,
  6. Robert H. Shoemaker3,
  7. David S. Waugh1,*

Article first published online: 2 DEC 2008

DOI: 10.1002/pro.16

Issue

Protein Science

Protein Science

Volume 18, Issue 1, pages 92–100, January 2009

Additional Information

How to Cite

Lountos, G. T., Tropea, J. E., Zhang, D., Jobson, A. G., Pommier, Y., Shoemaker, R. H. and Waugh, D. S. (2009), Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Science, 18: 92–100. doi: 10.1002/pro.16

Author Information

  1. 1

    Macromolecular Crystallography Laboratory, National Cancer Institute at Frederick, P. O. Box B, Frederick, Maryland 21702-1201

  2. 2

    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

  3. 3

    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, P. O. Box B, Frederick, Maryland 21702-1201

*Macromolecular Crystallography Laboratory, National Cancer Institute at Frederick, P. O. Box B, Frederick, MD 21702-1201

Publication History

  1. Issue published online: 16 DEC 2008
  2. Article first published online: 2 DEC 2008
  3. Manuscript Accepted: 13 OCT 2008
  4. Manuscript Revised: 9 OCT 2008
  5. Manuscript Received: 25 AUG 2008

Funded by

  • NIH
  • National Cancer Institute
  • Center for Cancer Research

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (261K)

References

  • 1
    Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW ( 2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824–1827.
  • 2
    Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ ( 2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97: 10389–10394.
  • 3
    Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, De Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, Elledge SJ, Mak TW ( 2002) Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22: 6521–6532.
  • 4
    Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE ( 2000) Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 60: 5934–5936.
  • 5
    Ahn JY, Li X, Davis HL, Canman CE ( 2002) Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem 277: 19389– 19395.
  • 6
    Oliver AW, Paul A, Boxall KJ, Barrie SE, Aherne GW, Garrett MD, Mittnacht S, Pearl LH ( 2006) Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J 25: 3179–3190.
  • 7
    Wu X, Chen J ( 2003) Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis. J Biol Chem 278: 36163–36168.
  • 8
    Oliver AW, Knapp S, Pearl LH ( 2007) Activation segment exchange: a common mechanism of kinase autophosphorylation? Trends Biochem Sci 32: 351–356.
  • 9
    Pommier Y, Weinstein JN, Aladjem MI, Kohn KW ( 2006) Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res 12: 2657–2661.
  • 10
    Antoni L, Sodha N, Collins I, Garrett MD ( 2007) CHK2 kinase: cancer susceptibility and cancer therapy—two sides of the same coin? Nat Rev Cancer 7: 925–936.
  • 11
    Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW ( 2005) Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 11: 2855–2872.
  • 12
    Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J ( 2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864–870.
  • 13
    Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD ( 2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907–913.
  • 14
    DiTullio RA,Jr., Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, Halazonetis TD ( 2002) 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 4: 998–1002.
  • 15
    Bartek J, Lukas J ( 2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421–429.
  • 16
    Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC ( 2006) Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 66: 11576–11579.
  • 17
    Freiberg RA, Hammond EM, Dorie MJ, Welford SM, Giaccia AJ ( 2006) DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol 26: 1598–1609.
  • 18
    Zhou BB, Anderson HJ, Roberge M ( 2003) Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther 2: S16–S22.
  • 19
    Zhou BB, Sausville EA ( 2003) Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 5: 413–421.
  • 20
    Levesque AA, Eastman A ( 2007) p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis 28: 13–20.
  • 21
    Yu Q, Rose JH, Zhang H, Pommier Y ( 2001) Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett 505: 7–12.
  • 22
    Sharma V, Hupp CD, Tepe JJ ( 2007) Enhancement of chemotherapeutic efficacy by small molecule inhibition of NF-κB and checkpoint kinases. Curr Med Chem 14: 1061–1074.
  • 23
    Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K, Motoyama N ( 2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 21: 5195–5205.
  • 24
    Arienti KL, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, Neff DK, Huang L, Crawford S, Pandit CR, Karlsson L, Breitenbucher JG ( 2005) Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 48: 1873–1885.
  • 25
    Curman D, Cinel B, Williams DE, Rundle N, Block WD, Goodarzi AA, Hutchins JR, Clarke PR, Zhou BB, Lees-Miller SP, Anderson RJ, Roberge M ( 2001) Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 276: 17914–17919.
  • 26
    Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y ( 2002) UCN-01 inhibits p53 up-regulation and abrogates γ-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 62: 5743–5748.
  • 27
    Sharma V, Tepe JJ ( 2004) Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett 14: 4319–4321.
  • 28
    Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D ( 2007) Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6: 935–944.
  • 29
    Jobson AG, Cardellina JH, 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y ( 2007) Identification of a bis-guanylhydrazone [4,4′-diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol 72: 876–884.
  • 30
    Neff DK, Lee-Dutra A, Blevitt JM, Axe FU, Hack MD, Buma JC, Rynberg R, Brunmark A, Karlsson L, Breitenbucher JG ( 2007) 2-Aryl benzimidazoles featuring alkyl-linked pendant alcohols and amines as inhibitors of checkpoint kinase Chk2. Bioorg Med Chem Lett 17: 6467–6471.
  • 31
    Huse M, Kuriyan J ( 2002) The conformational plasticity of protein kinases. Cell 109: 275–282.
  • 32
    Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J ( 2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9: 268–272.
  • 33
    Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C ( 2003) Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci USA 100: 12654–12659.
  • 34
    Lin X, Murray JM, Rico AC, Wang MX, Chu DT, Zhou Y, Del Rosario M, Kaufman S, Ma S, Fang E, Crawford K, Jefferson AB ( 2006) Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg Med Chem Lett 16: 4163–4168.
  • 35
    Kumar A, Mandiyan V, Suzuki Y, Zhang C, Rice J, Tsai J, Artis DR, Ibrahim P, Bremer R ( 2005) Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 348: 183–193.
  • 36
    Toledo LM, Lydon NB, Elbaum D ( 1999) The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 6: 775–805.
  • 37
    Scapin G ( 2002) Structural biology in drug design: selective protein kinase inhibitors. Drug Discov Today 7: 601–611.
  • 38
    Fischer PM ( 2004) The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr Med Chem 11: 1563–1583.
  • 39
    Foloppe N, Fisher LM, Francis G, Howes R, Kierstan P, Potter A ( 2006) Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. Bioorg Med Chem 14: 1792–1804.
  • 40
    Jin L, Pluskey S, Petrella EC, Cantin SM, Gorga JC, Rynkiewicz MJ, Pandey P, Strickler JE, Babine RE, Weaver DT, Seidl KJ ( 2004) The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors. J Biol Chem 279: 42818–42825.
  • 41
    Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Glimer TM, Shewchuk L ( 2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652–6659.
  • 42
    Buchanan SG ( 2003) Protein structure: discovering selective protein kinase inhibitors. Targets 2: 101–108.
  • 43
    Noble ME, Endicott JA, Johnson LN ( 2004) Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800–1805.
  • 44
    Tropea JE, Cherry S, Nallamsetty S, Bignon C, Waugh DS ( 2007) A generic method for the production of recombinant proteins in Escherichia coli using a dual hexahistidine-maltose-binding protein affinity tag. Methods Mol Biol 363: 1–19.
  • 45
    Kapust RB, Tozser J, Fox JD, Anderson DE, Cherry S, Copeland TD, Waugh DS ( 2001) Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng 14: 993–1000.
  • 46
    Minor W, Cymborowski M, Otwinowski Z, Chruszcz M ( 2006) HKL-3000: the integration of data reduction and structure solution–from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr 62: 859–866.
    Direct Link:
  • 47
    Matthews BW ( 1968) Solvent content of protein crystals. J Mol Biol 33: 491–497.
  • 48
    Potterton E, Briggs P, Turkenburg M, Dodson E ( 2003) A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr 59: 1131–1137.
    Direct Link:
  • 49
    Read RJ ( 1997) Model phases: probabilities and bias. Methods Enzymol 277: 110–128.
  • 50
    Emsley P, Cowtan K ( 2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
    Direct Link:
  • 51
    Brunger AT ( 1992) Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355: 472–475.
  • 52
    Schuttelkopf AW, van Aalten DM ( 2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355–1363.
    Direct Link:
  • 53
    Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB,III, Snoeyink J, Richardson JS, Richardson DC ( 2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35: W375–W383.
View Full Article (HTML) Get PDF (261K)